Atopic Dermatitis: Interesting News on Drug Candidates in Phase III

At the 2026 Annual Meeting of the American Academy of Dermatology (AAD), the latest study data on amlitelimab and rademikibart, among other topics, were presented during Late-Breaking Research sessions. The results underscore the therapeutic potential of these drug candidates—key endpoints were met, the safety profile was generally favorable, and, like other monoclonal antibodies, amlitelimab and rademikibart also demonstrate the advantage of convenient long-term use.